Treatment patterns of romosozumab in postmenopausal women with severe osteoporosis in Denmark: findings from the ROmosozumab in Scandinavia real-world Evidence Study (ROSES).

ABSTRACT:

Purpose

To describe patient and prescriber characteristics and factors associated with utilization of romosozumab in Denmark.

Methods

This registry‑based Danish retrospective cohort study comprised females aged ≥ 50 receiving osteoporosis medication from September 2020 - October 2023. Three cohorts were identified: those treated with romosozumab (cohort 1), those with osteoporosis‑related fracture within the last three years treated with other osteoporosis medications (cohort 2), and those without osteoporosis‑related fracture within three years prior to initiating other osteoporosis medications (cohort 3). Patient and prescriber characteristics are presented by cohort. Factors associated with receiving romosozumab and transition of treatment are reported.

Results

Ove

SUBMITTER: Langdahl BL 

PROVIDER: S-EPMC12847144 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature